Low-dose doxepin formulations and methods of making and using the same
AssigneePernix Sleep, Inc.
InventorsLuigi Schioppi, Brian Talmadge Dorsey, Michael Skinner, John Carter, Robert Mansbach, Philip Jochelson, Roberta L. Rogowski, Cara Casseday, Meredith Perry, Bryan Knox
Life of this patent
Estimating the term…
Abstract
The invention disclosed herein generally relates to low-dose oral doxepin pharmaceutical formulations and the use of these formulations to promote sleep.
Claims20
A pharmaceutical composition comprising from about 0.5 to about 7 mg of doxepin, or a pharmaceutically acceptable salt or prodrug thereof, and from about 20% to about 99.9% w/w silicified microcrystalline cellulose, the composition having one or more of the characteristics selected from the group consisting of:
- a hardness value of at least 2 Kp, a friability value of 1% or less, a disintegration time of about 1 minute as per USP protocols, at least an 80% release of doxepin within 15 minutes using compendial method for measuring dissolution of doxepin, at least an 85 percent release of doxepin within 30 minutes using U.S. Pharmacopeia (USP) Apparatus I at 100 rpm (or Apparatus II at 50 rpm) in 0.1 N HCl or Simulated Gastric Fluid USP without enzymes, at least an 85 percent release of doxepin within 30 minutes using U.S. Pharmacopeia (USP) Apparatus I at 100 rpm (or Apparatus II at 50 rpm) in a pH 4.5 buffer, and at least an 85 percent release of doxepin within 30 minutes using U.S. Pharmacopeia (USP) Apparatus I at 100 rpm (or Apparatus II at 50 rpm) in a pH 6.8 buffer or Simulated Intestinal Fluid USP without enzymes.
A method of manufacturing a doxepin dosage, doxepin salt or doxepin prodrug form comprising,
- forming a drug substance pre-blend by mixing a first filler and doxepin, doxepin salt or doxepin prodrug;
- forming a final blend by mixing a second filler and the drug substance pre-blend;
- forming a doxepin, doxepin salt or doxepin prodrug dosage form from the final blend.
A pharmaceutical unit dosage form, comprising:
- doxepin, a pharmaceutically-acceptable salt thereof or a prodrug thereof in an amount equivalent to about 3 or 6 mg doxepin hydrochloride;
- one or more pharmaceutically-acceptable excipients;
- and optionally,
- a capsule or coating;
- wherein the excipients and any capsule or coating are selected to provide a swallowable unit dosage that is at least externally solid and that has dissolution and bioavailablity characteristics such that after administration to a 70 kg human, the dosage form provides a plasma concentration of at least 0.1 ng/mL doxepin within a time frame of not more than about 60 minutes.
Dependencies are inferred from the claim text.